• Lupin receives USFDA approval for Testosterone Gel 1.62%

    • April 12, 2019
    • Posted By : admin
    • 0 Comment
    •   60 views

    Lupin has received approval for its Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie, Inc’s (AbbVie) AndroGel 1.62%.

    Lupin’s Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie’s AndroGel, 1.62%.

    It is indicated for replacement therapy in males for conditions assoc iated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired)

    Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), (RLD: AndroGel) had annual sales of approximately USD 893 million in the US (IQVIA MAT December 2018).

     

  60 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!